Forskningsgruppe for hjernemetastaser


There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there

Repurposing antipsychotics for treatment of brain metastasis

Drug repurposing involves the investigation of existing drugs for new therapeutic purposes. The drugs have already been approved for use in humans, thus new treatments for cancers can be offered to patients more quickly.


It is well known that cancer patients with brain metastasis (BM) have a poor prognosis and current treatments are not effective. Drugs specifically targeting BM are not available, and the patients have been excluded from clinical trials for many years.

Delivery of novel treatments such as targeted therapies and immunotherapies do not easily cross the blood-brain barrier (BBB), which is intact during early phases of BM development. In this respect, drugs which can penetrate an unimpaired BBB is warranted and we have previously shown that antipsychotics are able to cross an intact BBB and inhibit MBM development in animal models (ref).

We have at present convincing preliminary data, showing that the antipsychotic medications clozapine and thioridazine effectively inhibit melanoma brain metastasis progression in vitro (see Fig). This project encompass groups with strong expertise in medicinal chemistry and drug development and our group that has developed state-of-the art in vivo BM model systems. We aim to synthesize and test new analogues of clozapine and thioridazine, perform extensive screening of the analogues using our in vivo model systems of human BM, as well as cell lines and brain organoids in vitro. The project will provide potential new therapeutic options for BM patients with a poor prognosis.